|
Pluristem Announces its Appointment to the Advisory Board of The
Stem Cell Partnering Series
Tuesday October 7, 7:00 am ET
|
|
|
NEW YORK--(BUSINESS WIRE)--Pluristem
Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a
bio-therapeutics company dedicated to the commercialization
of non- personalized (allogeneic) cell therapy products for
a variety of degenerative, ischemic and autoimmune
indications, announced today it had been appointed to the
Advisory Board of The Stem Cell Partnering Series.
The Stem Cell Partnering Series is a
not-for-profit organization that actively supports the
development and sustainability of the stem cell industry by
fostering business collaborations and career development.
The Stem Cell Partnering Series' mandate is
to address two key challenges currently facing the stem cell
industry:
The 2nd annual Stem Cell Partnering
Series' meetings, the Fostering Business Collaborations
meeting and the Fostering Careers in Stem Cell Science
meeting, provide exclusive and targeted forums for
stakeholders in the stem cell industry to meet and
collaborate on the issues affecting their interests.
Zami Aberman, Pluristem’s
President and CEO commented, “Pluristem
is honored to be appointed to the Advisory Board of such
a prestigious and dedicated organization and to join
other esteemed Board members such as the Juvenile
Diabetes Research Foundation International (JDRF), the
Biotechnology Program at UC Davis, and the International
Society for Cellular Therapy (ISCT).”
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a
bio-therapeutics company dedicated to the
commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe
degenerative, ischemic and autoimmune disorders. The
Company is developing a pipeline of products, stored
ready-to-use, that are derived from human placenta, a
non-controversial, non-embryonic, adult stem cell
source.
These placental adherent stromal cells (ASCs)
are expanded in the Company's proprietary PluriXTM
3D bioreactor, which imitates the natural microstructure
of bone marrow and does not require supplemental growth
factors or other exogenous materials. Pluristem believes
that the resultant PLX (PLacental eXpanded) cells’
efficacy may be related to the secretion of cytokines or
other potent immune modulators. Furthermore, PLX cells
are immune privileged and possess immunomodulatory
properties, thus protecting the recipient from
immunological reactions that often accompany
transplantations.
Pluristem's first product in
development, PLX-PAD, is intended to improve the quality
of life of millions of people suffering from peripheral
artery disease (PAD). The Company's products in
development also include PLX-IBD, targeting Inflammatory
Bowel Disease (IBD); PLX-MS, targeting Multiple
Sclerosis; PLX-BMT, targeting the global shortfall of
matched tissue for bone marrow transplantation (BMT) by
improving the engraftment of hematopoietic stem cells
(HSCs) contained in umbilical cord blood; and
PLX-STROKE, targeting ischemic stroke.
Pluristem has offices in the USA with
research and manufacturing facilities in Israel.
See our product animation on YouTube:
http://www.youtube.com/watch?v=QzAANdeg0b0, the
content of which is not part of this press release.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and federal securities
laws. Whenever we use words such as "believe", "expect",
"anticipate", "intend", "plan", "estimate" or similar
expressions, we are making forward-looking statements.
These forward-looking statements are based on the
current expectations of the management of Pluristem
only, and are subject to a number of factors and
uncertainties that could cause actual results to differ
materially from those described in the forward-looking
statements. The following factors, among others, could
cause actual results to differ materially from those
described in the forward-looking statements: failure to
obtain required regulatory approvals, changes in
technology and market requirements; our technology may
not be validated as we progress further and our methods
may not be accepted by the scientific community; we may
be unable to retain or attract key employees whose
knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop
with our process; results in the laboratory may not
translate to equally good results in real surgical
settings; our patents may not be sufficient; our
products may harm recipients; changes in legislation;
inability to timely develop and introduce new
technologies, products and applications; loss of market
share and pressure on pricing resulting from
competition, which could cause the actual results or
performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except
as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these
forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the
occurrence of unanticipated events. For a more detailed
description of the risk and uncertainties affecting
Pluristem, reference is made to Pluristem's reports
filed from time to time with the Securities and Exchange
Commission.
Contact:
Pluristem
William Prather RPh, MD, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
Source:
Pluristem Therapeutics Inc.
|
|
|
|
